Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin II for refractory hypotension in paediatric distributive shock (phase III)
2025-523750-14-00Phase 3Authorised
- Sponsor
- PAION AG
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of Angiotensin II in Vasoplegia (2 arms), sponsored by PAION AG. Primary endpoint: Primary: Change in SOC vasopressor dose (NED sum/hour) from baseline to first 6 hours. Planned start Apr 2026; status: authorised.
02
Drugs
Angiotensin II
03
Conditions
Vasoplegia
Beyond the preview
Go deeper on 2025-523750-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523750-14-00.